Soon, injection or throat spray for kids with obstructive sleep apnea
By ANIFriday, February 5, 2010
WASHINGTON - A new study has found that kids with obstructive sleep apnea (OSA) may one day be able to have an injection or use a throat spray instead of getting their tonsils removed to cure their snoring.
The study from the University of Chicago found that a specific gene product might be responsible for the proliferation of adenotonsillar tissue that can cause pediatric OSA.
“We found that in the tonsil tissues of children with OSA, certain genes and gene networks were over expressed,” David Gozal, M.D., professor and chair of the Department of Pediatrics, who led the study, said.
“We believe that the results of this gene overexpression is increased proliferation of the adenotonsillar tissues, which in turn can cause partial or complete obstruction of the upper airways during sleep,” he stated.
Dr. Gozal and colleagues have been studying potential non-surgical alternatives to treat OSA in children.
To identify potential pharmacological targets, they recruited 18 children with OSA and 18 age-, gender-, and ethnicity-matched children with recurrent tonsillar infections (RI), all of who underwent surgery to have their tonsils removed.
The tonsil tissue from each subject was analysed for relative expression of the 44,000 known genes in the human genome.
The researchers then further analysed the gene pathways to determine which changes may represent differences with a high likelihood of impact on cellular proliferation.
“We wanted to find the most important and functionally pertinent genes, those with the most connectivity,” explained Dr. Gozal.
“We identified 47 genes and among those, two specific genes, both phosphatases, which are known to be very important at regulating communication in cells.
“Then we looked at the expression of the phosphatase protein and found that children with OSA have higher level of phosphatases in the tonsils,” he said.
In particular, they focused on one protein called phosphoserine phosphatase (PSPH) that was expressed in children with OSA, but almost never expressed in the children with RI.
“We asked, ‘What happens if we block this phosphatase?’ ‘Is this a potential target for pharmacological therapy?’” ” Dr. Gozal said.
Indeed, they found that introducing calyculin, a phosphatase inhibitor, reduced the cell proliferation and increased programmed cell death, or apoptosis, a process by which cells self-regulate, in the tonsils of OSA patients.
“Together, these observations suggest that PSPH is a logical therapeutic target in reversing adenotonsillar enlargement in pediatric OSA,” Dr. Gozal wrote.
“The next direction is to identify if selective clones of proliferating cells that may be affected by PSPH or by another of the discovered target genes with the intent of developing a non-surgical alternative treatment to surgery for OSA in children.
“If there is a subgroup of cells that have specific markers, then we may be able to develop a therapy that could be specifically targeted to these cells.
“Phosphatases such as PSPH are an exciting prospective target for therapy in children with OSA.
“We believe if we had effective non-surgical alternatives to tonsillectomies, it would be of great benefit,” he added.
The findings have been published online ahead of print publication in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine. (ANI)
